Ken Griffin Altimmune, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $381,150 - $561,330	69,300 Added 47.24%	216,000 $1.33 Million
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $606,366 - $1.05 Million	-102,600 Reduced 41.16%	146,700 $975,000
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $280,302 - $470,921	-34,100 Reduced 12.03%	249,300 $2.54 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $352,244 - $1.91 Million	164,600 Added 138.55%	283,400 $3.19 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $82,080 - $117,990	34,200 Added 40.43%	118,800 $308,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $627,555 - $1.09 Million	-181,900 Reduced 68.26%	84,600 $298,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $721,099 - $2.9 Million	172,100 Added 182.31%	266,500 $1.12 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $1.34 Million - $2.53 Million	-153,600 Reduced 61.94%	94,400 $1.55 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $2.35 Million - $4.93 Million	220,100 Added 788.89%	248,000 $3.17 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $426M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.